Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. The study suggests factors that make it more likely patients would forgo the treatment (Abstract 2195).

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.